Bioanalysis
A Multi-Peptide Hybrid LC-MS/MS Assay for the Determination of CTI-1601 in Monkey Tissues Provides Insight into its Disposition and Processing
Understanding Vaccines and Immunization
Your Immune System is your Body’s Defense Against Infection
You may already know that vaccines wor
Quantitation of a PEGylated Human Parathyroid Hormone (1-34) Analog in Rat Plasma Using a Hybrid Immunoaffinity Bottom-Up LC-MS/MS Assay
The Application of Light-Absorbing Photostabilizers for the Determination of Protoporphyrin IX in Human Plasma by LC-MS/MS
Overcoming Recovery Challenges in Hemolyzed Samples for the Determination of Propafenone and 5-Hydroxy Propafenone by LC-MS/MS
Method Development for the Detection of Exicure’s AST-008 in Human Plasma
A Lesson in Adaptability for the Determination of Rifampin
ISSUE NO. 8 — Bioanalytical Challenges Encountered when Developing ADA Assays
Following the approval in 1986 of Orthoclone OKT3, the first therapeutic monoclonal antibody product, a class of new protein-based therapeutic drugs was introduced and became the dominant product class within the biopharmaceutical market.
Today, several monoclonal antibodies have been approved for the treatment of a variety of diseases, ranging from those that target orphan disease indications with a small patient population, to those that target much larger patient populations and demographics, such as for oncology, asthma, and rheumatoid arthritis.
In Issue 8 of The Altascientist, we explore the role of anti-drug antibodies (ADAs) in therapeutic development, their impact on efficacy, and detection strategies, including:
- Challenges encountered in ADA assays
- Cell-based or non-cell-based assays to measure neutralization
- How Altasciences can help
ISSUE NO. 4 — Key Considerations for Biosimilar Clinical Pharmacology Studies
Selective Quantitation of 1,3-Propanediol in Dog Plasma Using Differential Ion Mobility Spectrometry